Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKF-1 (Ketotifen) in Acute Allergic Conjunctivitis
NCT01561521Phase 3Completed
- Sponsor
- Akorn
- Start
- Mar 2012
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketotifen in allergic conjunctivitis (AC) (3 arms), sponsored by Akorn. Primary endpoints: Ocular Itching at Day 14 and Ocular Redness at Day 14. Started Mar 2012; status: completed.
02
Drugs
ketotifen
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01561521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561521.